Raise closed, search for fresh raises on Seedstage

Seattle, WA

Opticyte’s VitalO₂ device aims to improve patient care by enabling accurate oxygen monitoring across skin tones and early sepsis detection.

• Mission: Improving patient care in critical healthcare settings by providing accurate oxygen monitoring and early detection of sepsis, particularly addressing health equity across diverse skin tones.  
• Innovation: The VitalO₂ device combines advanced pulse oximetry with noninvasive cellular oxygen measurement, enabling real-time monitoring of both blood and organ oxygen levels.  
• Market Opportunity: Targeting high-stakes healthcare environments such as ICUs, emergency rooms, and operating rooms to address gaps in oxygen measurement accuracy and early sepsis detection.  
• Regulatory Advantage: FDA Breakthrough Device Designation for accelerated approval, positioning Opticyte for a strong market entry within the next two years.  
• Health Equity Impact: Overcoming limitations in traditional pulse oximetry, especially for individuals with darker skin tones, to provide more accurate and timely clinical interventions.  
• Clinical Relevance: Enhancing the ability of healthcare providers to detect early signs of sepsis and organ failure, helping to reduce mortality and improve patient outcomes.

Opticyte is addressing critical gaps in healthcare with its innovative VitalO₂ device, a dual-function medical tool designed to provide accurate oxygen measurements across all skin tones and enable early detection of sepsis. This cutting-edge device combines advanced pulse oximetry with noninvasive cellular oxygen measurement, offering clinicians the ability to assess both blood and organ oxygen levels in real time. By providing this comprehensive view, VitalO₂ helps healthcare providers detect early signs of sepsis and organ failure, particularly addressing the issue of inaccurate oxygen readings in individuals with darker skin tones.

Opticyte’s solution has already garnered FDA Breakthrough Device Designation, allowing for accelerated regulatory review and positioning the company for a strong market entry. With substantial backing from the NIH and other investors, Opticyte is rapidly advancing in clinical testing and is projected to enter the market within two years. This innovative approach to sepsis detection and oxygen monitoring has the potential to transform patient care in intensive care units, emergency rooms, and other critical healthcare settings worldwide.

Company Info

Supporting the development of technology to advance early sepsis detection and equitable healthcare.

Opticyte is a medical device company focused on developing the VitalO₂, a device designed to enhance patient monitoring in critical care. This innovative technology combines advanced pulse oximetry with cellular oxygen measurement, allowing clinicians to obtain real-time, noninvasive data on both blood and cellular oxygen levels. VitalO₂ aims to address limitations in existing pulse oximeters, particularly issues with accuracy across various skin tones, which became increasingly apparent during the COVID-19 pandemic. By providing accurate measurements, it helps prevent treatment delays for patients with darker skin tones.

Additionally, the VitalO₂ device facilitates early detection of sepsis, a major cause of death in hospitals, enabling quicker clinical interventions. Opticyte’s device is targeted for use in high-stakes healthcare settings, such as intensive care units, operating rooms, and emergency departments. With its FDA Breakthrough Device Designation, Opticyte is positioned as a frontrunner in critical care innovation, striving to improve patient outcomes and reduce healthcare disparities in emergency medicine.